Immunovaccine appoints new CEO; PaxVax inks herpes R&D pact;

> Immunovaccine ($IMV) has appointed Marc Mansour as CEO. Release

> NovaDigm Therapeutics has acquired the rights to three Candida vaccine antigens. Release

> PaxVax has signed an R&D collaboration with UC San Diego to develop a vaccine against herpes simplex virus infections. Release

> Australian company Admedus has raised 10.1 million AUD ($9.4 million) in a share purchase plan for therapeutic vaccines. More

> UNICEF has handed over 15 generators to Liberia's government to ensure proper and safe vaccine storage. Release

And Finally... 108 countries are better than the U.S. at vaccinating against measles. More

Suggested Articles

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Sanofi's cost cuts are adding up, execs said in an update Wednesday. The company has trimmed nearly €1 billion in annual expenses so far in 2020.

Shingrix sales in the second quarter plummeted by half from first-quarter levels, and recovery of vaccination rates remains slow amid the pandemic.